Editors' ChoiceMEDICINE Targeting EGFR fusions in lung cancer Leslie K. FerrarelliScience Signaling, AAAS, Washington, DC 20005, USA See allHide authors and affiliations Science Signaling 14 Jun 2016:Vol. 9, Issue 432, pp. ec138DOI: 10.1126/scisignal.aag3308 Leslie K. Ferrarelli , AAAS, Washington, DC 20005, USAFind this author on Google Scholar Find this author on PubMed Search for this author on this site Article Info & Metrics eLetters Article Information vol. 9 no. 432 ec138 DOI: https://doi.org/10.1126/scisignal.aag3308 Published By: Science Signaling Print ISSN: 1945-0877 Online ISSN: 1937-9145 History: . Copyright & Usage: Copyright © 2016, American Association for the Advancement of Science Author Information Leslie K. FerrarelliScience Signaling, AAAS, Washington, DC 20005, USA Altmetric Article usage Article lifetimeLast 6 monthsThis monthArticle usage: June 2016 to February 2021 AbstractFullPdf Jun 2016300900 Jul 201615300 Aug 20168000 Sep 20169200 Oct 20166700 Nov 201610903 Dec 20164500 Jan 20177200 Feb 20174500 Mar 20173300 Apr 20173100 May 20172400 Jun 20172300 Jul 20172600 Aug 20175200 Sep 20174200 Oct 20173900 Nov 20172900 Dec 20173500 Jan 20183000 Feb 20183500 Mar 20182700 Apr 20183100 May 20183200 Jun 20183600 Jul 20183300 Aug 20182301 Sep 20181600 Oct 20182600 Nov 20184000 Dec 20184400 Jan 20194500 Feb 20193100 Mar 20193100 Apr 20191400 May 20192000 Jun 20192100 Jul 20192200 Aug 20191700 Sep 20191300 Oct 20192000 Nov 20191200 Dec 20191200 Jan 2020800 Feb 20201900 Mar 20201701 Apr 20201200 May 2020600 Jun 20201100 Jul 20201700 Aug 2020700 Sep 2020900 Oct 20201500 Nov 20201400 Dec 20202401 Jan 20211900 Feb 2021600 View Abstract
Targeting EGFR fusions in lung cancer By Leslie K. Ferrarelli Science Signaling14 Jun 2016 : ec138 Lung cancers with EGFR fusions are also sensitive to kinase inhibitors that target EGFR with activating mutations.
Targeting EGFR fusions in lung cancer By Leslie K. Ferrarelli Science Signaling14 Jun 2016 : ec138 Lung cancers with EGFR fusions are also sensitive to kinase inhibitors that target EGFR with activating mutations.